Sandoz US and its Fougera Pharmaceuticals subsidiary will pay a total of $265m to direct purchaser plaintiffs in US antitrust litigation over generic pricing, as part of a deal that the generics giant has reached to resolve the matter in exchange for “full release of all claims by the class.”
Sandoz Agrees $265m Settlement To Resolve US Pricing Litigation
Firm Says Purchasers Deal Underscores ‘Commitment To Integrity And Sound Governance’
Sandoz has agreed a $265m settlement in the US to resolve generic pricing antitrust class action litigation with direct purchaser plaintiffs, as part of a deal that contains no admission of wrongdoing on the part of the generics giant.
